Regeneron Pharmaceuticals (LTS:0R2M) Current Deferred Revenue: $685 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0R2M Regeneron Pharmaceuticals Inc LTS:0R2M
91 GF Score
Price $807.31
GF Value $875.78
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Regeneron Pharmaceuticals Current Deferred Revenue?

Regeneron Pharmaceuticals LTS:0R2M +0.64% 91 Current Deferred Revenue is $685 Mil as of Jun. 2026. GuruFocus rates LTS:0R2M with a GF Score™ of 91/100 and a GF Value™ of $875.78 (Fairly Valued). The stock has 7 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Regeneron Pharmaceuticals's current deferred revenue for the quarter that ended in Jun. 2026 was $685 Mil.

Regeneron Pharmaceuticals Current Deferred Revenue Related Terms

Regeneron Pharmaceuticals Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Regeneron Pharmaceuticals's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regeneron Pharmaceuticals Current Deferred Revenue Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 442.00 477.90 458.90 627.70 553.00

Regeneron Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 481.90 545.60 553.00 636.20 684.80
LTS:0R2M
91GF Score
Regeneron Pharmaceuticals Inc LTS:0R2M
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $685 Mil mean?
Regeneron Pharmaceuticals (LTS:0R2M) has a Current Deferred Revenue of $685 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Regeneron Pharmaceuticals and its competitors.
Is Regeneron Pharmaceuticals' Current Deferred Revenue too high?
Regeneron Pharmaceuticals' current Current Deferred Revenue is $685 Mil. Overall, Regeneron Pharmaceuticals has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' Current Deferred Revenue compare to RVMD and ALNY?
Regeneron Pharmaceuticals' Current Deferred Revenue of $685 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Regeneron Pharmaceuticals and its competitors. Regeneron Pharmaceuticals's current Current Deferred Revenue is $685 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (LTS:0R2M) is currently considered Fairly Valued. The stock's GF Value™ is $875.78, compared to a current price of $807.31 — trading 7.8% below its estimated fair value. The current Current Deferred Revenue is $685 Mil. Regeneron Pharmaceuticals' overall GF Score™ is 91/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Regeneron Pharmaceuticals (LTS:0R2M), the current Current Deferred Revenue is $685 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Regeneron Pharmaceuticals (LTS:0R2M) Overvalued in 2026?

Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued. The current stock price of $807.31 is trading 7.8% below its estimated GF Value™ of $875.78. GuruFocus considers Regeneron Pharmaceuticals to be Fairly Valued.

Key valuation signals for LTS:0R2M:

  • Current Deferred Revenue: $685 Mil
  • GF Value™: $875.78 vs. price of $807.31 (7.8% below fair value)
  • GF Score™: 91/100 with 7 warning signs

No single metric tells the full story. See the LTS:0R2M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Regeneron Pharmaceuticals Business Description

Address 777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
91GF Score

Get the complete analysis for LTS:0R2M

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$807.31
Price
$875.78
GF Value